MAP2K7 and Miyoshi myopathy: The combination of the MEK inhibitor Cobimetinib and BRAF inhibitor Vemurafenib with anti-PD-1 antibody Atezolizumab showed better PFS in patients with metastatic MM than those treated with Cobimetinib and Vemurafenib [111].